CY1108194T1 - Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων - Google Patents

Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων

Info

Publication number
CY1108194T1
CY1108194T1 CY20081100736T CY081100736T CY1108194T1 CY 1108194 T1 CY1108194 T1 CY 1108194T1 CY 20081100736 T CY20081100736 T CY 20081100736T CY 081100736 T CY081100736 T CY 081100736T CY 1108194 T1 CY1108194 T1 CY 1108194T1
Authority
CY
Cyprus
Prior art keywords
antibodies
patient
cancer
antitumor
production
Prior art date
Application number
CY20081100736T
Other languages
English (en)
Inventor
David S. F. Young
Miyoko Takahashi
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1108194T1 publication Critical patent/CY1108194T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο παραγωγής εξειδικευμένων για έναν ασθενή αντικαρκινικών αντισωμάτων με τη χρήση ενός νέου υποδείγματος διαλογής. Δια διαχωρισμού των αντικαρκινικών αντισωμάτων με τη χρήση της κυτταροτοξικότητας των καρκινικών κυττάρων ως τελικού σημείου, η μέθοδος καθιστά δυνατή την παραγωγή αντικαρκινικών αντισωμάτων εξατομικευμένων για το συγκεκριμένο ασθενή τα οποία μπορούν να χρησιμοποιηθούν για θεραπευτικούς και διαγνωστικούς σκοπούς. Η εφεύρεση αναφέρεται περαιτέρω στη μέθοδο δια της οποίας παρασκευάζονται τα αντισώματα και στις μεθόδους χρήσεως τους. Τα αντισώματα μπορούν να παρασκευασθούν ειδικά για έναν όγκο προερχόμενο από ένα συγκεκριμένο ασθενή και επιλέγονται με βάση την κυτταροτοξικότητά τους κατά καρκινικών κυττάρων και την ταυτόχρονη έλλειψη τοξικότητας προς τα μη καρκινικά κύτταρα. Τα αντισώματα μπορούν να χρησιμοποιηθούν για την υποβοήθηση της ταξινομήσεως και της διαγνώσεως ενός καρκίνου και μπορούν να χρησιμοποιηθούν για την αγωγή μεταστάσεων όγκου. Τα αντικαρκινικά αντισώματα μπορούν να συζευγνύονται με ερυθρά αιμοσφαίρια λαμβανόμενα από τον ασθενή και να επανεγχύονται για την αγωγή μεταστάσεων βασιζόμενη στην αναγνώριση ότι οι μεταστατικοί καρκίνοι παρουσιάζουν συνήθως καλή αγγείωση και η διανομή αντικαρκινικών αντισωμάτων από ερυθρά αιμοσφαίρια μπορεί να έχει ως αποτέλεσμα τη συγκέντρωση των αντισωμάτων στη θέση του όγκου.
CY20081100736T 2000-11-08 2008-07-14 Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων CY1108194T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/002050 WO2003074568A1 (en) 2000-11-08 2000-11-08 Individualized anti-cancer antibodies

Publications (1)

Publication Number Publication Date
CY1108194T1 true CY1108194T1 (el) 2012-05-23

Family

ID=27772923

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100736T CY1108194T1 (el) 2000-11-08 2008-07-14 Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων

Country Status (11)

Country Link
EP (2) EP1878749A3 (el)
JP (1) JP4826697B2 (el)
AT (1) ATE394425T1 (el)
AU (1) AU2001226985B8 (el)
CA (1) CA2456077A1 (el)
CY (1) CY1108194T1 (el)
DE (1) DE60038824D1 (el)
DK (1) DK1360208T3 (el)
ES (1) ES2306677T3 (el)
PT (1) PT1360208E (el)
WO (1) WO2003074568A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
WO1994018345A1 (en) * 1993-02-05 1994-08-18 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
ES2247204T3 (es) * 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.

Also Published As

Publication number Publication date
CA2456077A1 (en) 2003-09-12
EP1878749A3 (en) 2008-03-19
JP4826697B2 (ja) 2011-11-30
WO2003074568A1 (en) 2003-09-12
ATE394425T1 (de) 2008-05-15
WO2003074568A9 (en) 2003-12-11
DK1360208T3 (da) 2008-08-25
AU2001226985B8 (en) 2008-03-13
EP1360208A1 (en) 2003-11-12
AU2001226985A1 (en) 2003-09-16
DE60038824D1 (de) 2008-06-19
EP1878749A2 (en) 2008-01-16
ES2306677T3 (es) 2008-11-16
JP2005519120A (ja) 2005-06-30
PT1360208E (pt) 2008-06-11
EP1360208B1 (en) 2008-05-07
AU2001226985B2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
CY1108194T1 (el) Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων
DK1718737T3 (da) Cancerøs sygdomsmodificerende antistoffer
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
RU2011146654A (ru) Способы лечения рака яичников с применением конъюгированного средства
MXPA03001634A (es) Polipeptido tumoral cripto.
RS105304A (en) Methods of treating angiogenesis,tumor growth,and metastasis
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
US20050226882A1 (en) Method and multicomponent conjugates for treating cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
EA200501197A1 (ru) Композиции и способы для лечения злокачественной опухоли с применением igsf9 и liv - 1
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
MX2023010825A (es) Metodos para tratar el cancer con anticuerpos anti-ilt3.
Agaugué et al. The high expression of NKG2D ligands on tumor and non-tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D-based therapeutic approaches for cancer
JPWO2020257536A5 (el)
EP1929034A4 (en) ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE
AU2002348101A1 (en) Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
WO2022033978A3 (en) Cancer treatment methods using anti-cd73 antibodies
TH89330A (th) สารผสมที่ถูกปรับปรุงใหม่สำหรับการรักษามะเร็ง
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.